Work

Abstract 4394: GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-4394

Authors: Jonathan A. Pachter, Feng Yan, Silvia Coma, Cristina Caffarra Malvezzi, Xiuting Liu, Emilia Berardelli, Tao Jiang, Siyuan Le, Nathan Sanburn, Fusheng Zhou, Jiong Lan, David G. DeNardo, Chiara Ambrogio, Qiang Lu

Institutions: Verastem (United States), Genfleet Therapeutics (Shanghai) Inc. (China), University of Turin, Washington University in St. Louis

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409636096

Cites:

Cited by: 11

Related to: 10